BAX vs HSIC: fair value comparison
Baxter International Inc. and Henry Schein, Inc. · Updated 2026-09-06
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, BAX currently sits closer to the top of our discount ranking.
| BAX | HSIC | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $25.83 | $89.81 |
| 12-month range | $16.78–$28.10 | $63.20–$88.52 |
| Sector rank | #66 of 113 Healthcare | #70 of 113 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Stable |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BAX fair value analysis · HSIC fair value analysis